Gelteq FY2026: AUD$25.8M Loss, Full Intangible Write-Down, Going-Concern Warning
GELS is trading near its 52-week low of $0.348 (3.3% above the low).
Summary
Gelteq's FY2026 annual report shows a AUD$25.8M loss driven by a full AUD$18.9M intangible write-down, a going-concern warning, AUD$4.27M of debt in default, and only AUD$132,583 of cash.
Key Events · Earnings and Guidance · GELS
-
Full Intangible Write-Down Drives AUD$25.8M Loss
FY2026 net loss was AUD$25,781,515 versus AUD$6,645,453 in FY2025, including an AUD$18,940,468 impairment that reduced intangible assets from AUD$19,857,973 to nil.
-
Going-Concern Warning From Auditor
M&K CPAS, PLLC added an explanatory going-concern paragraph; working capital deficit was AUD$7,652,441 at June 30, 2026 and cash was only AUD$132,583.
-
AUD$4.27M of Borrowings in Default
Borrowings in default totaled AUD$4,265,508, comprising convertible notes of AUD$1,366,149, shareholder loans of AUD$2,885,809 and a director loan of AUD$13,550.
-
Nasdaq Bid Price Deadline March 15, 2027
A March 18, 2026 deficiency letter for trading below $1.00 was extended on September 15, 2026, giving the company until March 15, 2027 to regain compliance.
Analysis · GELS · Life Sciences
Gelteq's first audited annual report since listing shows a business running on fumes. The AUD$25.8M loss is mostly a non-cash AUD$18.9M write-off of the entire intangible asset base — management concluded historical consumer-health sales were far below forecast, so the acquired IP now carries zero book value. Strip that out and the operating loss was still roughly AUD$6.8M against zero revenue. The auditor added a going-concern paragraph, cash sits at just AUD$132,583, and AUD$4.27M of convertible notes and shareholder loans are formally in default. Funding comes from discounted convertible notes (93% of VWAP, with trigger provisions that can inflate the balance) and a Lincoln Park equity line, both of which dilute existing holders. Add a Nasdaq minimum-bid deficiency that must be cured by March 15, 2027, and a board now down to one director, and the thesis is survival, not growth.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GELS was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $0.35 to $2.01. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.